Unveiling the Molecular Mechanisms Driving the Capsaicin-Induced Immunomodulatory Effects on PD-L1 Expression in Bladder and Renal Cancer Cell Lines.

PD-L1 bladder cancer capsaicin genitourinary cancer immunotherapy renal cell carcinoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
26 May 2022
Historique:
received: 05 04 2022
revised: 16 05 2022
accepted: 23 05 2022
entrez: 10 6 2022
pubmed: 11 6 2022
medline: 11 6 2022
Statut: epublish

Résumé

The blockade of the PD-L1/PD-1 immune checkpoint has promising efficacy in cancer treatment. However, few patients with bladder cancer (BC) or renal cell carcinoma (RCC) respond to this approach. Thus, it is important to implement a strategy to stimulate the immune anti-tumor response. In this scenario, our study evaluated the effects of a low capsaicin (CPS) dose in BC and RCC cell lines. Western blot, qRT-PCR and confocal microscopy were used to assess PD-L1 mRNA and protein expression. Alterations to the cellular oxidative status and changes to the antioxidant NME4 levels, mRNA modulation of cytokines, growth factors, transcriptional factors and oncogene, and the activation of Stat1/Stat3 pathways were examined using Western blot, cytofluorimetry and qRT-PCR profiling assays. In BC, CPS triggers an altered stress oxidative-mediated DNA double-strand break response and increases the PD-L1 expression. On the contrary, in RCC, CPS, by stimulating an efficient DNA damage repair response, thus triggering protein carbonylation, reduces the PD-L1 expression. Overall, our results show that CPS mediates a multi-faceted approach. In modulating PD-L1 expression, there is a rationale for CPS exploitation as a stimulus that increases BC cells' response to immunotherapy or as an immune adjuvant to improve the efficacy of the conventional therapy in RCC patients.

Identifiants

pubmed: 35681623
pii: cancers14112644
doi: 10.3390/cancers14112644
pmc: PMC9179445
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Miur
ID : PRIN 2017

Références

Cancer Res. 2011 Apr 15;71(8):2809-14
pubmed: 21487045
Biochem Biophys Res Commun. 2004 May 14;317(4):1037-44
pubmed: 15094373
JAKSTAT. 2013 Oct 1;2(4):e25764
pubmed: 24416651
Phytother Res. 2006 Apr;20(4):303-6
pubmed: 16557614
Eur J Surg Oncol. 2014 Jan;40(1):121-7
pubmed: 24140000
Theranostics. 2021 Jan 1;11(4):1970-1981
pubmed: 33408792
Am J Cancer Res. 2019 Jun 01;9(6):1172-1182
pubmed: 31285950
Carcinogenesis. 2009 Aug;30(8):1320-9
pubmed: 19502594
Protein Cell. 2017 Mar;8(3):169-177
pubmed: 28044278
Oncotarget. 2016 Aug 2;7(31):50180-50194
pubmed: 27367032
Cancers (Basel). 2021 Sep 02;13(17):
pubmed: 34503236
Temperature (Austin). 2015 May 07;2(2):166-7
pubmed: 27227019
J Neuroinflammation. 2018 Oct 17;15(1):290
pubmed: 30333036
BMC Cancer. 2016 Oct 12;16(1):790
pubmed: 27729033
Oncotarget. 2018 Sep 18;9(73):33865
pubmed: 30333916
Growth Factors. 2005 Sep;23(3):177-82
pubmed: 16243709
Biochem Biophys Res Commun. 2020 May 21;526(1):29-34
pubmed: 32192776
Acta Pharmacol Sin. 2018 Mar;39(3):438-448
pubmed: 29188798
Signal Transduct Target Ther. 2017;2:
pubmed: 28515962
Nat Commun. 2019 Oct 25;10(1):4871
pubmed: 31653838
Nat Immunol. 2014 Nov;15(11):1055-1063
pubmed: 25282159
Cancer Manag Res. 2018 Jun 22;10:1647-1655
pubmed: 29970964
Eur J Pharmacol. 2020 Nov 15;887:173356
pubmed: 32763303
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Am Soc Clin Oncol Educ Book. 2018 May 23;38:197-207
pubmed: 30231333
PLoS One. 2013 Dec 30;8(12):e83971
pubmed: 24386318
Cancer Lett. 2012 Nov 1;324(1):91-7
pubmed: 22579786
J Clin Pharm Ther. 2020 Feb;45(1):16-28
pubmed: 31545523
Urology. 2010 Mar;75(3):735-41
pubmed: 19592070
Lab Invest. 2018 May;98(5):582-588
pubmed: 29491425
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Sci Rep. 2021 Jul 23;11(1):15134
pubmed: 34302052
Science. 1998 Sep 11;281(5383):1674-7
pubmed: 9733514
J Cell Biochem. 2018 Dec;119(12):9997-10004
pubmed: 30145830
J Bioenerg Biomembr. 2000 Jun;32(3):237-46
pubmed: 11768307
Oncogene. 2004 Nov 4;23(52):8545-51
pubmed: 15361851
Crit Rev Food Sci Nutr. 1991;29(6):435-74
pubmed: 2039598
Molecules. 2016 Oct 21;21(10):
pubmed: 27775662
Future Sci OA. 2015 Nov 01;1(3):FSO15
pubmed: 28031890
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Expert Opin Ther Targets. 2018 Jun;22(6):547-557
pubmed: 29702007
Redox Biol. 2014 Jan 30;2:590-8
pubmed: 24688895
Immunity. 2007 Jul;27(1):111-22
pubmed: 17629517
Int J Mol Sci. 2021 Jan 09;22(2):
pubmed: 33435349
Nat Neurosci. 2002 Sep;5(9):856-60
pubmed: 12161756
Eur Urol. 2013 May;63(5):881-9
pubmed: 23084331
EMBO J. 1999 Apr 1;18(7):1815-23
pubmed: 10202145
Life Sci. 2020 Apr 1;246:117403
pubmed: 32035131
Ann Oncol. 2014 Nov;25(11):2178-2184
pubmed: 25193987
Target Oncol. 2016 Apr;11(2):143-8
pubmed: 26429561
Eur Urol. 2012 Aug;62(2):303-14
pubmed: 22575911
Int Immunol. 2020 Feb 7;32(2):73-88
pubmed: 31555812
Front Immunol. 2018 Jun 06;9:1273
pubmed: 29928281
Cancers (Basel). 2021 Nov 28;13(23):
pubmed: 34885101
Front Immunol. 2020 Nov 09;11:595207
pubmed: 33240283
BMC Urol. 2018 Nov 6;18(1):97
pubmed: 30400941
Blood. 2007 Jul 1;110(1):296-304
pubmed: 17363736
Cancer. 2014 Jan 1;120(1):86-95
pubmed: 24122346
Molecules. 2016 Jun 28;21(7):
pubmed: 27367652
Int J Vitam Nutr Res. 1998;68(2):114-9
pubmed: 9565827
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
Drugs Today (Barc). 2017 Apr;53(4):217-237
pubmed: 28492290
Oncol Rep. 2015 Jun;33(6):3075-84
pubmed: 25963805
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):117-122
pubmed: 28302417
Cells. 2019 Oct 18;8(10):
pubmed: 31635402
J Exp Clin Cancer Res. 2018 May 11;37(1):103
pubmed: 29751820
Int J Mol Sci. 2020 Jul 17;21(14):
pubmed: 32708927
J Biol Chem. 2008 Sep 19;283(38):26198-207
pubmed: 18635542
Cancer Sci. 2009 Nov;100(11):2093-100
pubmed: 19703193
J Inflamm Res. 2021 Oct 13;14:5241-5249
pubmed: 34675601
Free Radic Res. 2006 Sep;40(9):966-73
pubmed: 17015277
Cell Stress Chaperones. 2013 Nov;18(6):801-8
pubmed: 23580156
Int Urol Nephrol. 2021 Dec;53(12):2493-2503
pubmed: 33797012
Onco Targets Ther. 2018 May 16;11:2891-2899
pubmed: 29844686
J Biol Chem. 1998 Mar 6;273(10):5858-68
pubmed: 9488723
Cancer Res. 2019 Aug 1;79(15):3940-3951
pubmed: 31101760
Sci Rep. 2016 Dec 21;6:39618
pubmed: 28000761
J Immunol. 2007 Mar 1;178(5):3260-4
pubmed: 17312175

Auteurs

Maria Beatrice Morelli (MB)

School of Pharmacy, University of Camerino, 62032 Camerino, Italy.

Oliviero Marinelli (O)

School of Pharmacy, University of Camerino, 62032 Camerino, Italy.

Cristina Aguzzi (C)

School of Pharmacy, University of Camerino, 62032 Camerino, Italy.

Laura Zeppa (L)

School of Pharmacy, University of Camerino, 62032 Camerino, Italy.

Massimo Nabissi (M)

School of Pharmacy, University of Camerino, 62032 Camerino, Italy.

Consuelo Amantini (C)

School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy.

Daniele Tomassoni (D)

School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy.

Federica Maggi (F)

School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy.

Matteo Santoni (M)

Medical Oncology Unit, Hospital of Macerata, 62100 Macerata, Italy.

Giorgio Santoni (G)

School of Pharmacy, University of Camerino, 62032 Camerino, Italy.

Classifications MeSH